Immunotherapy, Immunobiomarkers and Gene Analysis Role in the Improvement of Lung Cancer Treatment

Lung cancer is the second most common with a poor survival rate (18.6%). Recently treatment of lung has been improved starting from choosing appropriate by gene and immunobiomarkers analysis to immunotherapy which played major role in showed improvement overall (OS), progression-free (PFS) objective response (ORR) less adverse effects. Through this triad Immunotherapy, Gene oncologists can provide better for patients. The important cause that makes shows good results P53 mutation present more than half causes high genetic instability so mutations cells neoantigens are formed. These make immunogenic respond immunotherapy. drug family effective Immune checkpoint inhibitors. Throughout journey inhibitors develop resistance multiple mechanisms discussed review overcome these be used combination other immunotherapies or radiotherapy.